Midatech Pharma Share Discussion Threads

[dice1950] 10/8/2016 09:03

MIDATECH PHARMA (MTPH)BUY Buy Target price 273.09p Potential +102.3%
…

[dice1950] 10/8/2016 08:56

!YOUTUBEVIDEO:hdvE3jUFoxs:
Midatech Pharma sees H1 revenue up at £3.8m
10 August 2016


Will Midatech Pharma plc be the next Shire plc?

[fillipe] 10/8/2016 08:48

Quite something of an RNS today....!



SP up 18%, on quite small.....waiting for a wider audience to latch to MTPH.

f

[luffness] 18/5/2016 18:41

Not too bothered about the transbuccal insulin trial - it always seemed a bit of an outlier for them - but not surprised by the market reaction

Was rather hoping for more news on MTX110 though

[hutch_pod] 18/5/2016 17:03

Finally got round to watching the Rising stars presentation posted above (thx Deltrotter). He is really on form.

I had been very focused on the Insulin results, mainly due to an old Edison note breaking out potential NPVs, but it does seem things have moved on quite a lot (just as well). Helpful that he throws out target revenues too for his products.

[thomasthetank1] 18/5/2016 12:10

Read Panmure Gordon & Co's note on MIDATECH PHARMA PLC (MTPH), out this morning, by visiting hxxps://www.research-tree.com/company/GB00BRTL9B63

"Midatech Pharma has announced updates across five of its eight R&D programmes this morning. While the MidaForm Phase IIa trial (transbuccal insulin) has disappointed on the basis of low bioavailability, positive updates across MTX110 (DIPG), MTX102 (vaccine against type 1 diabetes), glioblastoma and hepatocellular carcinoma (MTR103 and MTR104) candidate selection and Q-Octreotide (MTD201) demonstrate the breadth of the opportunity which continues to grow. Midatech’s story has always been one of ‘multiple shots on goal’ and..."

[mfhmfh] 18/5/2016 09:57

A mixed bag overall.

Insulin trial - big disappointment. But looks like our technology is more suited to oncology.

Brain tumour treatment has been expanded: 'rapidly advance this programme approximately one year ahead of schedule.' 'Within the United States, interest in using the treatment at other centres is under evaluation with the FDA.'

Q-Octreotide programme (MTD201): 'Pilot preclinical study confirmed the systemic release profile of Midatech's Q-Octreotide compared favourably with the current market leader, Sandostatin® LAR Depot (Novartis).'

[banshee] 18/5/2016 08:59

Lets hope so. If the DIPG treatment should return only marginal benefits that would not bode well for its other GNP chemo programs

[deltrotter] 18/5/2016 08:52

I am guessing that its continued use is pointing to positive results.

[banshee] 18/5/2016 08:43

Interesting co, the question is does today's (fairly predictable) failure of its oral insulin trial with low bio availability raise a similar question mark over all its Gold Nano Particle technology?

The DIPG results should answer this question once we get some hard data, fingers crossed for those afflicted with this terrible illness.

[thomasthetank1] 11/5/2016 14:12

Read Panmure Gordon & Co's note on MIDATECH PHARMA PLC (MTPH), out this morning, by visiting hxxps://www.research-tree.com/company/GB00BRTL9B63

"This morning Midatech Pharma has issued an AGM statement and trading update, reaffirming the continued progress seen at, and following, last month’s results. Management notes that strong revenues continue to be seen from the group’s marketed products and, as a result, trading is ‘slightly ahead’ of consensus market expectations. This is consistent with the outlook commentary we heard from the company on 13 April: on this basis, and bearing in mind our upper-end of range forecasts, we..."

[deltrotter] 11/5/2016 09:54

I am guessing the Bristol trial is going ok if they might now be undertaking something similar in the US.

Only a guess though.

[mfhmfh] 11/5/2016 09:49

No unexpected/negative surprises from the update today:

'In the first four months of 2016 we have seen strong revenues from our marketed products and as a result the Group is trading slightly ahead of consensus market expectations.'

Just waiting for the results of the 2 studies now.

[luffness] 11/5/2016 08:46

anyone going to the agm ?

[18bt] 11/5/2016 07:35

Strong AGM statement

[mfhmfh] 09/5/2016 20:44

European Mediscience Awards 2016 - we're shortlisted for Best Technology Award

hxxp://www.mediscience-event.co.uk/awards/shortlist/

[luffness] 05/5/2016 16:18

The current products should take them to breakeven next year so cash raise unlikely

The team know what they are doing and as they put it they have multiple shots on goal - only one of which needs to hit

eg diabetes - which isnt even their real focus (cancer treatments are) they have 2 bets - one the buccal film for insulin delivery and secondly the potential immunisation program

[knights] 05/5/2016 15:20

thanks for the link to the presentation.

I must admit, I had been expecting a placing to raise more cash. but I noticed that the CEO said in his presentation that he expects the cash they have to take them to profitability.

i have added to my position today. fingers crossed for good results on the upcoming diabetes trial.

Knights

[deltrotter] 03/5/2016 12:27

Thanks luffness. Just going to take time. I'll continue to buy bits and pieces going forward - although I have bought my largest share at nearly £3.

We'll get back to that price and more in the years to come IMO.

[luffness] 03/5/2016 11:51

yes all looking very positive -i think it is the university of san francisco where the program is about to start

[deltrotter] 03/5/2016 10:24

Great presentation - the compassionate use programme of their technology is soon to start in the US. A nice tidbit!

[deltrotter] 03/5/2016 10:10

Video of MTPH presentation at the Rising Stars: